The CML therapeutic imatinib and its derivative dasatinib inhibit the tyrosine kinase activity of BCR-ABL resulting in leukaemic cell death. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.